G Protein β3 Polymorphism and Triptan Response in Cluster Headache
G Protein β3 Polymorphism and Triptan Response in Cluster Headache
复制标题
G 蛋白 β3 多态性和丛集性头痛中曲普坦的反应
DOI：
10.1038/sj.clpt.6100159
复制
发表时间：
2007
影响因子：
6.7
通讯作者：
Dieter Rosskopf
中科院分区：
文献类型：
--
作者：
M. Schürks;Tobias Kurth;Tobias Kurth;P. Stude;C. Rimmbach;J. Jesus;Mira Jonjic;Hans;Dieter Rosskopf
只有大约70%的偏头痛和丛集性头痛（CH）患者报告对曲坦类药物有显著的治疗反应，曲坦类药物是属于G蛋白偶联受体家族的5‐HT1B/D受体的激动剂。我们分析了G蛋白β3亚基（GNB3 C825T）基因的共同多态性是否调节了231名无关高加索CH患者对曲坦类药物的应答率。共有180例CH患者使用曲坦类药物，其中71.1%报告治疗成功。GNB3 825T等位基因杂合携带者与825CC基因型携带者对曲坦类药物治疗反应的调整优势比为2.96（95%置信区间1.34-6.56；P=0.0074）。GNB3基因型状态不影响对其他急性和预防性治疗方案的反应，包括氧气、维拉帕米和皮质类固醇，即不直接影响G蛋白的药物。我们得出结论，曲坦类药物的疼痛缓解是由一种常见的GNB3基因变体显著调节的。
Only about 70% of migraine and cluster headache (CH) patients report significant treatment responses to triptans, which are agonists at 5‐HT1B/D receptors belonging to the family of G protein‐coupled receptors. We analyzed whether a common polymorphism in the gene for the G protein β3 subunit (GNB3 C825T) modulates responder rates to triptans among a cohort of 231 unrelated Caucasian CH patients. A total of 180 CH patients used triptans, of whom 71.1% reported treatment success. The adjusted odds ratio for treatment response to triptans for heterozygous carriers of the GNB3 825T allele was 2.96 (95% confidence interval 1.34–6.56; P=0.0074) vs carriers of the 825CC genotype. The GNB3 genotype status did not affect responses to other acute and preventive therapeutic regimes including oxygen, verapamil, and corticosteroids, i.e., drugs not directly affecting G proteins. We conclude that pain relief by triptans is significantly modulated by a common genetic GNB3 variant.